Search our Database of Scientific Publications and Authors

I’m looking for a

    2040 results match your criteria Angioimmunoblastic Lymphoma

    1 OF 41

    Indolent T-lymphoblastic proliferation concomitant to acinic cell carcinoma mimicking T-lymphoblastic lymphoma: case report and literature review.
    Histopathology 2017 Nov 15. Epub 2017 Nov 15.
    Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
    Aims: Indolent T-lymphoblastic proliferation (iT-LBP) is a non-clonal benign condition showing extrathymic proliferation of T-lymphoblasts positive for CD3, CD4, CD8, and TdT. Isolated iT-LBP has been observed, but the majority of iT-LBP have been seen in conjunction with other disorders including Castleman disease, hepatocellular carcinoma, follicular dendritic cell tumors, angioimmunoblastic T-cell lymphoma, myasthenia gravis, and acinic cell carcinoma (ACC). The clinical course of iT-LBP is indolent, and no therapy is usually required. Read More

    Programmed Death-1 Ligands, PD-L1 and PD-L2, Show Distinctive and Restricted Patterns of Expression in Lymphoma Subtypes.
    Hum Pathol 2017 Nov 6. Epub 2017 Nov 6.
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:
    The success of immunotherapy using immune checkpoint blockade in solid tumors and in relapsed/refractory classical Hodgkin lymphoma and chronic lymphocytic leukemia holds promise for targeted therapy in hematologic malignancies. Since efficacy of immunomodulatory therapy is correlated with numbers of cells that express programmed death (PD-1) ligands, we evaluated the expression of PD-L1 and PD-L2 proteins using immunohistochemistry in over 702 diagnostic lymphoma biopsies. In classical Hodgkin lymphoma, PD-L1 and PD-L2 were expressed in 82% and 41% of cases respectively, and PD-L1 but not PD-L2 expression correlated with Epstein Barr Virus in tumor cells. Read More

    Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Leuk Lymphoma 2017 Nov 9:1-10. Epub 2017 Nov 9.
    b The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
    We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28. Read More

    Lymphoproliferative Disorders with Concurrent HHV8 and EBV Infection: Beyond Primary Effusion Lymphoma and Germinotropic Lymphoproliferative Disorder.
    Histopathology 2017 Nov 3. Epub 2017 Nov 3.
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
    Aims: Lymphoproliferative disorders (LPD) characterized by human herpesvirus 8 (HHV8) and Epstein-Barr virus (EBV) infection are rare and two entities are included in the World and Health Organization classification: primary effusion lymphoma (PEL) and germinotropic LPD. These two entities have very different clinicopathological presentations and prognosis. Here we describe two cases of HHV8-positive, EBV-positive lymphoma with clinicopathological features that are not consistent with either PEL or germinotropic LPD. Read More

    Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma.
    Oncotarget 2017 Sep 17;8(44):76231-76240. Epub 2017 Jul 17.
    Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    Interleukin-10 (IL-10) induces an immunosuppressive microenvironment including M2 macrophages, inhibiting anti-tumor immunity. The aim of this study was to evaluate whether serum IL-10 level at diagnosis and tissue infiltration of M2 macrophages could predict survival outcome of patients with angioimmunoblastic T-cell lymphoma (AITL). We measured serum levels of IL-5, IL-10, IL-12, and interferon-gamma (IFN-γ) at diagnosis in AITL and other common subtypes of nodal T-cell lymphoma including peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), ALK-negative anaplastic large cell lymphoma (ALCL) or ALK-positive ALCL between September 2008 and December 2014. Read More

    Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: A multicenter phase II trial of West-JHOG PTCL0707.
    Haematologica 2017 Sep 29. Epub 2017 Sep 29.
    Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
    The standard CHOP for peripheral T-cell lymphoma has resulted in unsatisfactory outcomes and optimal frontline therapy remains unclear. We conducted a multicenter phase II study of dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone (EPOCH) for untreated peripheral T-cell lymphoma patients. In this prospective study, 41 patients were treated with dose-adjusted-EPOCH as initial therapy: peripheral T-cell lymphoma-not otherwise specified, n = 21; angioimmunoblastic T-cell lymphoma, n = 17; anaplastic lymphoma kinase-positive anaplastic large cell lymphoma, n = 2; and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma, n = 1. Read More

    Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor.
    Medicine (Baltimore) 2017 Sep;96(39):e8091
    aDepartment of Hematology, the First Affiliated Hospital of Zhejiang University bInstitute of Hematology, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
    Angioimmunoblastic T-cell lymphoma (AITL) is a major subtype of peripheral T-cell lymphoma (PTCL). Due to its low incidence, the characteristics of AITL are still not well understood. The prognostic evaluation of this disease has not been established. Read More

    Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas.
    Am J Surg Pathol 2017 Dec;41(12):1581-1592
    *Pathology Department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris †INSERM U955 équipe 9, Institut Mondor de Recherche Biomédicale ‡Paris Est Creteil University (UPEC) ¶Biological Immunology Department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris #Dermatology department, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris **Hematology Department, Lymphoid hemopathy Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil ††Dermatology Department, Saint-André Hospital, CHU de Bordeaux ‡‡INSERM U1053, Bordeaux Research in Translational Oncology, Team 3 Oncogenesis of Cutaneous Lymphomas, Bordeaux University, Bordeaux §Pathoogy department, Haut-Lévèque Hospital, CHU de Bordeaux §§Tumor Biology Department, Haut-Lévèque Hospital, CHU de Bordeaux, Pessac, France ∥Pathology Department Prof Lima Basto, Lisboa, Portugal.
    Skin biopsies of 41 angioimmunoblastic T-cell lymphoma patients were retrospectively analyzed for the expression of follicular helper T-cell (TFH) markers, Epstein-Barr virus (EBV), and the presence of RHOA (p.G17V) and IDH2 (p.R172K/S) mutations using allele-specific polymerase chain reaction. Read More

    CMIP is oncogenic in human gastric cancer cells.
    Mol Med Rep 2017 Nov 20;16(5):7277-7286. Epub 2017 Sep 20.
    Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China.
    Gastric cancer is one of the most common cancers and the second leading cause of cancer‑associated mortality worldwide. Recurrence, metastasis and resistance to drug treatment are the main barrier to survival of patients with advanced stage gastric cancer. Further study of the molecular mechanisms involved will improve the therapeutic options for gastric cancer. Read More

    Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma.
    Intern Med 2017 Nov 25;56(21):2851-2856. Epub 2017 Sep 25.
    Departments of Hematology and Laboratory Medicine, Aiseikai Yamashina Hospital, Japan.
    Objective It has been postulated that the normal counterpart of angioimmunoblastic T-cell lymphoma (AITL) is the follicular helper T-cell (TFH). Recent immunological studies have identified several transcription factors responsible for T-cell differentiation. The master regulators associated with T-cell, helper T-cell (Th), and TFH differentiation are reportedly BCL11B, Th-POK, and BCL6, respectively. Read More

    Study of association of Epstein-Barr virus in lymphomas by Epstein-Barr virus-encoded RNA in situ hybridization: An Indian perspective from a tertiary care cancer institute.
    Indian J Pathol Microbiol 2017 Jul-Sep;60(3):341-349
    Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
    Background: The Epstein-Barr virus (EBV), also called human herpesvirus 4, is a virus of the herpes family. The EBV-associated lymphomas include Burkitt lymphoma, classic Hodgkin lymphoma (HL), lymphomas arising in immunocompromised individuals, peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphoma, extranodal nasal-type natural killer/T-cell lymphoma, and other rare histotypes.

    Objective: The present study evaluated the role of EBV as an etiologic agent in various lymphomas and determined an Indian perspective in a tertiary care cancer center compared to that of Western literature. Read More

    A review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.
    Cancer Sci 2017 Sep 10. Epub 2017 Sep 10.
    Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
    Angioimmunoblastic T-cell lymphoma (AITL) is an age-related malignant lymphoma, characterized by immune system-dysregulated symptoms. Recent sequencing studies have clarified the recurrent mutations in ras homology family member A (RHOA) and in genes encoding epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2), DNA methyl transferase 3 alpha (DNMT3A), and isocitrate dehydrogenase 2, mitochondrial (IDH2), as well as those related to the T-cell receptor signaling pathway in AITL. In this review, we will focus on how this genetic information has changed the understanding of the developmental process of AITL and will in future lead to individualized therapies for AITL patients. Read More

    Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.
    Medicine (Baltimore) 2017 Sep;96(36):e8001
    aDivision of Gastroenterology and Hematology/Oncology, Department of Medicine bOncology Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
    Rationale: Hypereosinophilic syndrome (HES) is a rare disorder characterized by hypereosinophilia and organ damage. Some cases of HES are caused by the FIP1L1/PDGFRA fusion gene and respond to imatinib. FIP1L1/PDGFRA-positive HES occasionally evolves into chronic eosinophilic leukemia or into another form of myeloproliferative neoplasm; however, the development of a malignant lymphoma is very rare. Read More

    Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.
    Leukemia 2017 Aug 23. Epub 2017 Aug 23.
    Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
    Somatic G17V RHOA mutations were found in 50-70% of angioimmunoblastic T-cell lymphoma (AITL). The mutant RHOA lacks GTP binding capacity, suggesting defects in the classical RHOA signaling. Here, we discovered the novel function of the G17V RHOA: VAV1 was identified as a G17V RHOA-specific binding partner via high-throughput screening. Read More

    Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant 2017 Nov 7;23(11):1826-1838. Epub 2017 Aug 7.
    Vanderbilt University Medical Center, Nashville, Tennessee.
    Recognizing the significant biological and clinical heterogeneity of mature T cell and natural killer (NK)/T cell lymphomas, the American Society for Blood and Marrow Transplantation invited experts to develop clinical practice recommendations related to the role of autologous hematopoietic cell transplantation (auto-HCT) and allogeneic HCT (allo-HCT) for specific histological subtypes. We used the GRADE methodology to aid in moving from evidence to decision making and ultimately to generating final recommendations. Auto-HCT in front-line consolidation is recommended in peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma-anaplastic lymphoma kinase (ALCL-ALK)-negative, NK/T cell (disseminated), enteropathy-associated T cell lymphoma (EATL), and hepatosplenic lymphomas. Read More

    Lymphocytic hidradenitis: A distinctive histopathological finding of annular erythema of Sjögren syndrome.
    Australas J Dermatol 2017 Aug 3. Epub 2017 Aug 3.
    College of Medicine, Chang Gung University, Taoyuan, Taiwan.
    Background/objectives: Lymphocytic hidradenitis is a non-specific histopathological feature observed in many dermatoses such as lupus erythematosus, morphea or scleroderma. When it occurs it is usually accompanied by the other distinctive histological features of those conditions. Isolated lymphocytic hidradenitis is uncommon and its clinical features and associated underlying medical conditions are still undetermined. Read More

    Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.
    Cell Immunol 2017 Sep 10;319:28-34. Epub 2017 Jul 10.
    Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address:
    CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function. Read More

    Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis.
    J Clin Invest 2017 Aug 10;127(8):2998-3012. Epub 2017 Jul 10.
    Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology and.
    Angioimmunoblastic T cell lymphoma (AITL) represents a distinct, aggressive form of peripheral T cell lymphoma with a dismal prognosis. Recent exome sequencing in patients with AITL has revealed the frequent coexistence of somatic mutations in the Rho GTPase RhoA (RhoAG17V) and loss-of-function mutations in the 5-methylcytosine oxidase TET2. Here, we have demonstrated that TET2 loss and RhoAG17V expression in mature murine T cells cooperatively cause abnormal CD4+ T cell proliferation and differentiation by perturbing FoxO1 gene expression, phosphorylation, and subcellular localization, an abnormality that is also detected in human primary AITL tumor samples. Read More

    Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma.
    Ann Hematol 2017 Sep 20;96(9):1471-1475. Epub 2017 Jun 20.
    Department of Hematology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
    Recent genetic studies identified that the disease-specific G17V RHOA mutation, together with mutations in TET2, DNMT3A, and IDH2, is a hallmark of angioimmunoblastic T cell lymphomas (AITL). The diagnostic value of these mutations is now being investigated. Circulating tumor DNAs (ctDNAs) may offer a non-invasive testing for diagnosis and disease monitoring of cancers. Read More

    Profiling of peripheral T-cell lymphomas in Kerala, South India: A 5-year study.
    Indian J Pathol Microbiol 2017 Apr-Jun;60(2):206-208
    Division of Pathology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.
    Background: Peripheral T-cell lymphomas (PTCLs) are non-Hodgkin's lymphomas (NHLs) with considerable variation in incidence across the world. They show a wide variety of clinicopathological features and generally associated with poor clinical outcome. Lymphoma data from different geographic regions will definitely aid in routine clinical practice and research work. Read More

    Treatment of Peripheral T-Cell Lymphoma in Community Settings.
    Clin Lymphoma Myeloma Leuk 2017 Jun 10;17(6):354-361. Epub 2017 May 10.
    John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; COTA Inc, New York, NY. Electronic address:
    Background: Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of malignancies that do not have consensus treatment recommendations. Strategies extrapolated from B-cell lymphoma have met with limited efficacy, although T-cell-specific salvage therapies have been recently developed.

    Methods: To determine treatment patterns and associated outcomes in PTCL not otherwise specified (PTCL-NOS), anaplastic large T-cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma (AITL), a retrospective analysis was undertaken at a large US community oncology network among patients treated between January 2010 and April 2015. Read More

    Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome).
    Case Rep Dermatol 2017 Jan-Apr;9(1):74-79. Epub 2017 Mar 21.
    aDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
    Angioimmunoblastic T-cell lymphoma (AITCL) is a rare, aggressive lymphoma which derives from follicular helper T cells, commonly affecting the elderly population. It accounts for 2% of all non-Hodgkin lymphomas, with a reported 5-year overall survival rate of less than 30%. Very often, the clinical picture of AITCL encompasses systemic symptoms such as generalized lymphadenopathy, hepatosplenomegaly, skin rash, anemia, and polyclonal hypergammaglobulinemia. Read More

    Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification.
    J Pathol Transl Med 2017 Jul 5;51(4):352-358. Epub 2017 Jun 5.
    Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
    Epstein-Barr virus (human herpesvirus-4) is very common virus that can be detected in more than 95% of the human population. Most people are asymptomatic and live their entire lives in a chronically infected state (IgG positive). However, in some populations, the Epstein-Barr virus (EBV) has been involved in the occurrence of a wide range of B-cell lymphoproliferative disorders (LPDs), including Burkitt lymphoma, classic Hodgkin's lymphoma, and immune-deficiency associated LPDs (post-transplant and human immunodeficiency virus-associated LPDs). Read More

    Death caused by possible unrecognized (too Late Recognized) Mycobacterium gordonae infection in a patient with angioimmunoblastic T-cell lymphoma.
    Int J Mycobacteriol 2017 Apr-Jun;6(2):199-201
    Department of Hematology and Oncology, General Hospital Dr. Josip Benčević, Andrije Štampara 42, Slavonski Brod 35000, Croatia.
    Here, we present possible death caused by Mycobacterium gordonae infection in a patient with angioimmunoblastic T-cell lymphoma. Our patient was severely immunocompromised in whom we suspect to an infection, but we did not have isolates until she died. After she died, we received a positive sputum culture of M. Read More

    Unusual Histology in Hodgkin's Lymphoma: Report of an Interesting Case.
    Indian J Surg Oncol 2017 Jun 9;8(2):181-184. Epub 2016 Dec 9.
    Hamdard Institute of Medical Sciences and Research (HIMSR), New Delhi, India.
    Hodgkin's lymphoma has a significant presence in the Indian subcontinent. Microscopically, the hallmark of Hodgkin's lymphoma (HL) is the Hodgkin and Reed-Sternberg (HRS) cell, which is usually surrounded by a cellular infiltrate of non-malignant inflammatory cells that constitute the majority of the tumor tissue. Cells which are known to be histologic mimics of HRS cells include immunoblasts, plasmablasts and rarely dendritic cells. Read More

    Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells.
    J Pathol 2017 Aug 29;242(4):387-390. Epub 2017 Jun 29.
    Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
    Angioimmunoblastic T-cell lymphoma (AITL) is one of the most frequent entities of peripheral T-cell lymphoma. An AITL has two components: the AITL tumour cells, which have a T follicular helper (TFH) cell phenotype, and a surrounding and extensive tumour microenvironment that is populated with various reactive cell types, including B cells. Recurrent TET2 mutations have been described in 50-80% of AITLs, possibly occurring in a haematopoietic progenitor cell. Read More

    IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.
    J Cancer 2017 29;8(6):1018-1024. Epub 2017 Mar 29.
    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    Background: Interferon regulatory factor 4 (IRF4)/multiple myeloma oncogene-1 (MUM1) is a member of the interferon regulatory factor family of transcriptional factors. Although IRF4/MUM1 expression is associated with aggressiveness of B-cell lymphoma and multiple myeloma, the prognostic value of IRF4/MUM1 expression in peripheral T-cell lymphoma (PTCL) is unclear. Methods: We analyzed a tissue array from 69 patients diagnosed with PTCL. Read More

    The aggressive peripheral T-cell lymphomas: 2017.
    Am J Hematol 2017 Jul;92(7):706-715
    The Joe Shapiro Professor of Medicine, University of Nebraska Medical Center, 986840 Nebraska Medical Center, Omaha, NE, 68198.
    Background: T-cell lymphomas make up approximately 10%-15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.

    Diagnosis: The diagnosis of aggressive peripheral T-cell lymphoma (PTCL) is usually made using the World Health Organization classification. Read More

    Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.
    Front Oncol 2017 2;7:86. Epub 2017 May 2.
    Department of Biology, University of Nebraska at Omaha, Omaha, NE, USA.
    The role of the tumor microenvironment in leukemias and lymphomas is well established, yet the intricacies of how the malignant cells regulate and influence their non-malignant counterparts remain elusive. For example, chronic lymphocytic leukemia (CLL) is an expansion of malignant CD5(+)CD19(+) B cells, yet the non-malignant T cells play just as large of a role in disease presentation and etiology. Herein, we review the dynamic tumor cell to lymphoid repertoire interactions found in two non-Hodgkin's lymphoma subtypes: CLL and angioimmunoblastic T-cell lymphoma. Read More

    A Rare Case of Angioimmunoblastic T-Cell Lymphoma with Epstein-Barr Virus-Negative Reed-Sternberg-Like B-Cells, Chylous Ascites, and Chylothorax.
    Case Rep Hematol 2017 12;2017:1279525. Epub 2017 Apr 12.
    Department of Pathology, VieCuri Medical Centre, 5912 BL Venlo, Netherlands.
    Angioimmunoblastic T-cell lymphoma is a rare non-Hodgkin lymphoma with dismal prognosis. The median age of presentation ranges from 62 to 69 years with generalized lymphadenopathy, B symptoms, and hepatosplenomegaly as the most prevalent symptoms. The combination of B-cell and T-cell proliferations is common in AITL and the B-cell component may resemble Reed-Sternberg-like B-cells. Read More

    Cardiac Tamponade as Initial Presentation of Angioimmunoblastic T-Cell Lymphoma.
    Heart Surg Forum 2017 Mar 6;20(2):E043-E044. Epub 2017 Mar 6.
    Peking Union Medicine School Hospital, Cardiac Surgery Department, Peking.
    A 21-year-old man presented initially with impending cardiac tamponade secondary to an angioimmunoblastic T-cell lymphoma (AITL). Following unsuccessful pericardiocentesis and subxiphoid pericardiostomy, the patient's deteriorating hemodynamics prompted an urgent sternotomy. Histopathological diagnosis confirmed AITL. Read More

    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol 2017 Jun 1;35(18):2008-2017. Epub 2017 May 1.
    Camille Laurent, Nadia Amara, Georges Delsol, and Pierre Brousset, Institut Universitaire du Cancer-Oncopole de Toulouse; Centre Hospitalier Universitaire (CHU) Toulouse; Camille Laurent, Georges Delsol, and Pierre Brousset, Institut National de la Santé et de la Recherche Médicale (INSERM), U.1037, Centre de Recherche en Cancerologie de Toulouse-Purpan, Laboratoire d'Excellence Toulouse Cancer; Thomas Filleron, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse, Toulouse; Marine Baron, Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri Mondor-Albert Chenevier; Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, INSERM U955, Université Paris-Est, Créteil; Mylène Dandoit, Marc Maynadié, and Laurent Martin, CHU de Dijon, Dijon; Marie Parrens, Beatrice Vergier, and Antoine de Mascarel, Hôpital du Haut Lévêque, CHU de Bordeaux, Bordeaux; Bettina Fabiani, AP-HP, Hôpital Saint-Antoine; Nicole Brousse and Thierry Jo Molina, AP-HP, Hôpital Necker; Josette Brière, AP-HP, Hôpital Saint Louis; Fréderic Charlotte, AP-HP, Hôpital Pitié Salpétrière; Diane Damotte, AP-HP, Hôpitaux Universitaires Paris Centre, Paris; Alexandra Traverse-Glehen and Françoise Berger, CHU Lyon-Sud; Catherine Chassagne-Clement, Centre Léon Bérard, Lyon; Marie-Christine Copin, Univ Lille, CHU Lille, Lille; Patrick Tas, CHU de Rennes, Rennes; Marie-Christine Rousselet, CHU d'Angers, Angers; Thérèse Rousset, Hôpital Gui de Chauliac, CHU de Montpellier, Montpellier; Luc Xerri, Aix-Marseille Univ, Institut Paoli-Calmettes, Marseille; Anne Moreau and Céline Bossard, Hôpital Hôtel Dieu, CHU de Nantes, Nantes; Antoine Martin, Hôpital Avicenne, Bobigny, Bobigny; Peggy Dartigues, Institut Gustave Roussy, Villejuif; Isabelle Soubeyran, Institut Bergonié, Bordeaux; Michel Peoch, CHU de Saint Etienne, Saint Etienne; Pierre Dechelotte, CHU de Clermont-Ferrand, Clermont-Ferrand; Jean-François Michiels, CHU de Nice, Nice; Flavie Arbion, CHU de Tours, Tours; Isabelle Quintin-Roué, CHU de Brest, Brest; Jean-Michel Picquenot, Centre Henri Becquerel, CHU de Rouen, Rouen; Martine Patey, CHU de Reims, Reims; Blandine Fabre, CHU de Grenoble, Grenoble; Henri Sevestre, CHU d'Amiens, Amiens; Cécile Le Naoures, CHU de Caen, Caen; Marie-Pierre Chenard-Neu, CHU de Strasbourg, Strasbourg; Claire Bastien, CHU de Nancy, Nancy; Sylvie Thiebault, CH de Mulhouse, Mulhouse; Manuela Delage, CHU de Limoges, Limoges; Gilles Salles, Hospices Civils de Lyon, CHU Lyon-Sud; Gilles Salles, INSERM1052, Centre National de la Recherche Scientifique 5286, Université Claude Bernard, Pierre Bénite, France; Tony Petrella, Pathology University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Canada.
    Purpose To prospectively assess the clinical impact of expert review of lymphoma diagnosis in France. Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the Lymphopath Network. Changes in diagnosis between referral and expert review were classified as major or minor according to their potential impact on patient care. Read More

    Angioimmunoblastic T Cell lymphoma mimics reactive lymphoid tissue on cytomorphology: A multimodality approach utilising cytology, immunocytochemistry and flow cytometry to resolve this diagnostic dilemma.
    Cytopathology 2017 Jun 28;28(3):239-241. Epub 2017 Mar 28.
    Manchester Cytology Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK.

    Uncommon Variants of T-Cell Lymphomas.
    Hematol Oncol Clin North Am 2017 Apr;31(2):285-295
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill-Cornell Medical College, 1233 York Avenue, New York, NY 10022, USA. Electronic address:
    Peripheral T-cell lymphomas represent 10% to 15% of non-Hodgkin lymphomas and comprise more than 20 different entities. Treatment of very rare T-cell lymphomas can be challenging because there are no large or randomized studies to guide clinical decision making, and treatment paradigms are often based on small series or imperfect data. Although a strict algorithm cannot be written with certainty, through the literature that exists and clinical experience, themes and principles of approaches do emerge that when coupled with clinical judgment allow reasonable and logical decisions. Read More

    Angioimmunoblastic T-Cell Lymphoma.
    Hematol Oncol Clin North Am 2017 Apr;31(2):223-238
    Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Via Massarenti, 9, Bologna 40138, Italy. Electronic address:
    Angioimmunoblastic T-cell lymphoma is a follicular T-helper-derived neoplasm displaying a peculiar morphologic appearance and biological complexity. New mutations have been described that contribute to elucidating the underlying pathogenetic events. The disease behaves aggressively and typically affects elderly patients. Read More

    TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma.
    J Pathol 2017 Jun 3;242(2):129-133. Epub 2017 May 3.
    Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Medical School, Essen, Germany.
    Angioimmunoblastic T-cell lymphomas (AITLs) frequently carry mutations in the TET2 and IDH2 genes. TET2 mutations represent early genetic lesions as they had already been detected in haematopoietic precursor cells of AITL patients. We show by analysis of whole-tissue sections and microdissected PD1(+) cells that the frequency of TET2-mutated AITL is presumably even higher than reported (12/13 cases in our collection; 92%). Read More

    The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma 2017 Oct 17;58(10):2349-2355. Epub 2017 Mar 17.
    a Fujian Provincial Key Laboratory on Hematology , Fujian Medical University Union Hospital, Fujian Institute of Hematology , Fuzhou , Fujian , China.
    The aim of the study was to determine the clinical significance of EBV DNA in the peripheral blood mononuclear cells (PBMCs) from the patients with non-Hodgkin lymphoma (NHL). Newly diagnosed patients with NHL were enrolled in the study (n = 328), and clinical data retrospectively analyzed. EBV DNA was detectable in 34. Read More

    Genetic Landscape and Classification of Peripheral T Cell Lymphomas.
    Curr Oncol Rep 2017 Apr;19(4):28
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
    Purpose Of Review: Peripheral T cell lymphomas (PTCLs) are markedly heterogeneous at the clinical, pathological, and molecular levels. This review will discuss genetic findings in PTCL with special emphasis on how they impact lymphoma classification.

    Recent Findings: Sequencing studies have identified recurrent genetic alterations in nearly every PTCL subtype. Read More

    Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol 2017 Mar 13;35(9):955-962. Epub 2017 Feb 13.
    Andrea B. Moffitt and Sandeep S. Dave, Duke University, Durham, NC.
    In this review, we examine the genomic landscapes of lymphomas that arise from B, T, and natural killer cells. Lymphomas represent a striking spectrum of clinical behaviors. Although some lymphomas are curable with standard therapy, the majority of the affected patients succumb to their disease. Read More

    Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
    J Int Med Res 2017 Feb 12;45(1):290-302. Epub 2017 Jan 12.
    Peking Union Medical College Hospital (PUMCH), Beijing, China.
    Objective To determine the efficacy and prognosis of autologous hematopoietic stem cell transplantation (ASCT) as frontline treatment for peripheral T cell lymphoma (PTCL). Methods Clinical data from 46 PTCL patients who achieved complete (CR) or partial remission (PR) after ASCT from October 1996 to July 2014 were analysed retrospectively. Results Median patient age was 32 (range: 15-68) years. Read More

    Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.
    Clin Lymphoma Myeloma Leuk 2017 Apr 10;17(4):193-200. Epub 2017 Jan 10.
    Department of Medical Oncology, Yale University, New Haven, CT.
    Background: With increased understanding of the unique entities, subtype-specific approaches for peripheral T-cell lymphoma (PTCL) are emerging, and more precise diagnoses are becoming increasingly important. PATIENTS AND METHODS: We analyzed the approach to the histopathologic diagnosis of PTCL using data from the comprehensive oncology measures of peripheral T-cell lymphoma (COMPLETE) study. The COMPLETE trial is a large prospective cohort study of patients with newly diagnosed PTCL in the United States. Read More

    Angioimmunoblastic T-Cell Lymphoma: A Questionable Association with Follicular Dendritic Cell Sarcoma.
    Case Rep Hematol 2017 18;2017:9601094. Epub 2017 Jan 18.
    Department of Pathology, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
    An elderly woman presented with generalized lymphadenopathy, several systemic symptoms, and splenomegaly. An inguinal lymph node excision revealed a compound picture. One aspect of the lymph node morphology, including cells with follicular T-helper cell phenotype, was most consistent with angioimmunoblastic T-cell lymphoma. Read More

    Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma.
    Biomark Res 2017 8;5. Epub 2017 Feb 8.
    Department of Internal Medicine, Division of Hematology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
    Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common subtypes of peripheral T-cell lymphoma. Advances in understanding the mutational landscape of AITL have not resulted in improved prognosis nor consensus regarding optimal first-line and second-line treatment. The recently proposed multistep tumorigenesis model for AITL provides a theoretical framework of AITL oncogenesis. Read More

    Angioimmunoblastic T-Cell Lymphoma with Polyarthritis Resembling Rheumatoid Arthritis.
    Clin Med Res 2016 Dec;14(3-4):159-162
    Department of Pathology, Marshfield Clinic, Marshfield Wisconsin USA.
    Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma (PTCL). AITL typically presents with lymphadenopathy, fever, rash, hepatosplenomegaly, and rarely polyarthritis. We report the case of a 50-year-old female who presented with lymphadenopathy, rash, and symmetric polyarthritis. Read More

    Identification of cell-type-specific mutations in nodal T-cell lymphomas.
    Blood Cancer J 2017 Jan 6;7(1):e516. Epub 2017 Jan 6.
    Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
    Recent genetic analysis has identified frequent mutations in ten-eleven translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 2 (IDH2) and ras homolog family member A (RHOA) in nodal T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified. We examined the distribution of mutations in these subtypes of mature T-/natural killer cell neoplasms to determine their clonal architecture. Targeted sequencing was performed for 71 genes in tumor-derived DNA of 87 cases. Read More

    Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling.
    Oncotarget 2017 Mar;8(11):17763-17770
    Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.
    Angioimmunoblastic T cell lymphoma (AITL) originates from follicular helper T-cells and is characterised by a polymorphic infiltrate with the neoplastic T-cells forming small clusters around the follicle and high endothelial venules. Despite the recent advances in its phenotypic characterisation, the genetics and molecular mechanisms underlying AITL are not fully understood. In the present study, we performed whole exome sequencing in 9 cases of AITL from Taiwan (n = 6) and U. Read More

    1 OF 41